None, D. G. D., None, D. V. K., None, D. S. B. & None, D. S. M. (2026). Clinical Efficacy, Safety and Postoperative Outcomes of Thermal Balloon Endometrial Ablation for Abnormal Uterine Bleeding: A Retrospective Study of 14 Cases. Journal of Contemporary Clinical Practice, 12(11), 389-401.
MLA
None, Dr. Gauri Dank, et al. "Clinical Efficacy, Safety and Postoperative Outcomes of Thermal Balloon Endometrial Ablation for Abnormal Uterine Bleeding: A Retrospective Study of 14 Cases." Journal of Contemporary Clinical Practice 12.11 (2026): 389-401.
Chicago
None, Dr. Gauri Dank, Dr. Vaishali Khadke , Dr. Sandhya Bhattad and Dr. Sneha Muley . "Clinical Efficacy, Safety and Postoperative Outcomes of Thermal Balloon Endometrial Ablation for Abnormal Uterine Bleeding: A Retrospective Study of 14 Cases." Journal of Contemporary Clinical Practice 12, no. 11 (2026): 389-401.
Harvard
None, D. G. D., None, D. V. K., None, D. S. B. and None, D. S. M. (2026) 'Clinical Efficacy, Safety and Postoperative Outcomes of Thermal Balloon Endometrial Ablation for Abnormal Uterine Bleeding: A Retrospective Study of 14 Cases' Journal of Contemporary Clinical Practice 12(11), pp. 389-401.
Vancouver
Dr. Gauri Dank DGD, Dr. Vaishali Khadke DVK, Dr. Sandhya Bhattad DSB, Dr. Sneha Muley DSM. Clinical Efficacy, Safety and Postoperative Outcomes of Thermal Balloon Endometrial Ablation for Abnormal Uterine Bleeding: A Retrospective Study of 14 Cases. Journal of Contemporary Clinical Practice. 2026 Nov;12(11):389-401.
Clinical Efficacy, Safety and Postoperative Outcomes of Thermal Balloon Endometrial Ablation for Abnormal Uterine Bleeding: A Retrospective Study of 14 Cases
Dr. Gauri Dank
1
,
Dr. Vaishali Khadke
2
,
Dr. Sandhya Bhattad
3
,
Dr. Sneha Muley
4
1
Associate Professor, Department of OBGY, RKDMC SRIMS and Dr Hedgewar Rugnalaya, India.
2
Clinical HOD, Department of OBGY, Dr. Hedgewar Rugnalaya, India.
3
Consultant, Department of OBGY, Dr. Hedgewar Rugnalaya, India.
4
Assistant Professor, Department of OBGY, RKDMC SRIMS & Dr. Hedgewar Rugnalaya, India.
Background: Thermal balloon endometrial ablation is a minimally invasive treatment option for abnormal uterine bleeding in appropriately selected women who have completed childbearing. Assessment of postoperative outcomes and subsequent interventions is important for evaluating its clinical effectiveness and safety. Objective: To evaluate the clinical efficacy, procedural safety and postoperative outcomes of thermal balloon endometrial ablation, with particular emphasis on subsequent hysterectomy. Materials and Methods: A retrospective observational case series included 14 women who underwent thermal balloon endometrial ablation for abnormal uterine bleeding. Available clinical and operative records were reviewed for demographic characteristics, associated conditions, ultrasonographic findings, procedural parameters and postoperative outcomes. Hysterectomy-defined treatment failure was defined as subsequent hysterectomy for persistent or recurrent abnormal uterine bleeding. Continuous variables were summarised using mean and standard deviation or recorded ranges, and categorical variables using frequencies and percentages. Exact binomial 95% confidence intervals were calculated for binary outcomes. Results: Age was available for 13 women, with a mean of 44.31 ± 7.57 years and a range of 33-56 years; nine women (69.2%) were aged ≥40 years. All 14 patients completed thermal balloon ablation. Readable procedural entries documented balloon inflation volumes of 11-15 mL, temperatures of approximately 87-92°C and treatment duration of 12 minutes in several cases. Postoperative follow-up was described as uneventful in all patients. No postoperative complications or subsequent hysterectomies were recorded, corresponding to observed event proportions of 0.0% (95% CI: 0.0-23.2%). The hysterectomy-free proportion was 100.0% (95% CI: 76.8-100.0%). Bleeding resolution and amenorrhoea were not quantified, repeat interventions were not separately documented, and follow-up duration was unspecified. Conclusion: Thermal balloon endometrial ablation was associated with no recorded postoperative complications or subsequent hysterectomies in this small retrospective series. However, incomplete symptom assessment and undefined follow-up limited conclusions regarding clinical efficacy and long-term durability. Larger studies with standardised bleeding outcomes and defined follow-up are required.
Keywords
Abnormal uterine bleeding
Endometrial ablation
Thermal balloon ablation.
INTRODUCTION
Abnormal uterine bleeding (AUB) is one of the most common gynaecological complaints among women of reproductive and perimenopausal age, contributing substantially to impaired quality of life, iron-deficiency anaemia, psychological distress, and increased healthcare utilisation. It is characterised by abnormalities in the frequency, regularity, duration, or volume of menstrual bleeding and may arise from structural or non-structural causes. The International Federation of Gynecology and Obstetrics (FIGO) introduced the PALM-COEIN classification system to standardise the evaluation of AUB, categorising its causes into structural abnormalities, including polyps, adenomyosis, leiomyomas, and malignancy or hyperplasia, and non-structural abnormalities, including coagulopathy, ovulatory dysfunction, endometrial disorders, iatrogenic causes, and conditions not otherwise classified. Munro et al. (2018) emphasised the importance of systematic clinical assessment and accurate identification of underlying pathology for appropriate management of AUB [1].
Management of abnormal uterine bleeding includes pharmacological, minimally invasive, and definitive surgical approaches. Medical treatment commonly involves hormonal therapies, levonorgestrel-releasing intrauterine systems, antifibrinolytic agents, and non-steroidal anti-inflammatory drugs. However, medical management may be associated with inadequate symptom control, adverse effects, contraindications, or poor long-term compliance. Hysterectomy provides definitive treatment but involves major surgery, anaesthesia-related risks, postoperative morbidity, prolonged recovery, and potential psychological consequences. Consequently, minimally invasive uterine-preserving procedures have gained increasing importance in the management of women with AUB who have completed childbearing. NICE (2021) recommended consideration of endometrial ablation in appropriately selected women with heavy menstrual bleeding when medical treatment is unsuccessful, unsuitable, or declined [2].
Endometrial ablation is a minimally invasive procedure designed to destroy the functional and basal layers of the endometrium, thereby reducing or eliminating menstrual bleeding. Thermal balloon endometrial ablation represents a second-generation ablation technique in which a fluid-filled balloon is introduced into the uterine cavity and heated to a controlled temperature for a predetermined duration. The thermal energy produces coagulative necrosis of the endometrial tissue, resulting in subsequent fibrosis and reduced menstrual blood loss. The technique offers several potential advantages, including relatively short procedural duration, standardised energy delivery, avoidance of major abdominal surgery, and faster postoperative recovery. Daniels et al. (2012) demonstrated that second-generation endometrial ablation techniques were effective treatment options for heavy menstrual bleeding, although differences in effectiveness and patient satisfaction existed between individual devices [3].
The clinical success of thermal balloon endometrial ablation depends on appropriate patient selection, uterine cavity characteristics, underlying endometrial pathology, and procedural factors. Women with significant cavity distortion, suspected malignancy, active pelvic infection, or future fertility intentions are generally unsuitable candidates. Although endometrial ablation is associated with favourable outcomes in many patients, persistent or recurrent bleeding, pelvic pain, and subsequent hysterectomy remain important indicators of treatment failure. Long-term studies have demonstrated that the need for additional intervention may increase with the duration of follow-up. El-Nashar et al. (2009) identified clinical predictors of treatment failure following global endometrial ablation, highlighting the importance of preoperative assessment and patient counselling [4].
Postoperative evaluation is essential for determining the safety and effectiveness of thermal balloon endometrial ablation. Important outcome measures include improvement in menstrual bleeding, postoperative complications, additional medical or surgical treatment, patient satisfaction, and the requirement for hysterectomy. A Cochrane review by Bofill Rodriguez et al. (2019) highlighted the effectiveness of endometrial destruction techniques while recognising that repeat intervention may be required in some patients [5].
AIM
To evaluate the clinical efficacy, procedural safety, and postoperative outcomes of thermal balloon endometrial ablation in women with abnormal uterine bleeding, with particular emphasis on procedural failure and the requirement for subsequent hysterectomy.
OBJECTIVES
1. To assess the clinical efficacy of thermal balloon endometrial ablation in the management of abnormal uterine bleeding, including postoperative symptomatic improvement and treatment success.
2. To evaluate the safety and postoperative outcomes of thermal balloon endometrial ablation, including intraoperative complications, postoperative complications, and recovery during the follow-up period.
3. To determine the procedural failure rate following thermal balloon endometrial ablation, particularly the requirement for repeat surgical intervention or hysterectomy due to persistent or recurrent abnormal uterine bleeding.
MATERIALS AND METHODS
Source of Data
The present study was conducted using retrospectively collected clinical and procedural records of women who underwent thermal balloon endometrial ablation for abnormal uterine bleeding at a tertiary care hospital. Data were obtained from gynaecology outpatient records, inpatient case files, operative registers, ultrasonography reports, preoperative investigations, discharge summaries, and available postoperative follow-up records. The study included 14 women who underwent thermal balloon endometrial ablation as a minimally invasive treatment for abnormal uterine bleeding.
Information regarding demographic characteristics, obstetric history, presenting complaints, previous medical and surgical conditions, ultrasonographic findings, endometrial thickness, uterine cavity length, procedural parameters, intraoperative events, postoperative recovery, and subsequent requirement for hysterectomy was reviewed. Patient confidentiality was maintained by assigning unique study identification numbers and excluding personally identifiable information from the analytical dataset.
Study Design
The study was designed as a single-centre, hospital-based, retrospective observational case series involving 14 women who underwent thermal balloon endometrial ablation for abnormal uterine bleeding.
The study evaluated procedural characteristics, safety, postoperative recovery, and documented treatment failure. No control group or random allocation was involved.
Study Location
The study was carried out in the Department of Obstetrics and Gynaecology of a tertiary care teaching hospital.
The hospital provided outpatient consultation, diagnostic ultrasonography, hysteroscopic assessment, operative gynaecological services, and postoperative follow-up facilities.
The hospital name and location should be inserted before manuscript submission.
Study Duration
The study period covered the dates of thermal balloon endometrial ablation procedures documented in the institutional records. The supplied case sheets include procedures performed across different calendar years, with records extending into 2026.
The retrospective review included the available postoperative follow-up period for each patient. Follow-up information was assessed up to the last documented clinical contact.
Study period: From [earliest eligible procedure date] to [latest eligible procedure date].
Follow-up duration: From the date of the procedure to the last documented follow-up visit.
The exact study period and minimum, median, and maximum follow-up durations should be established from the complete clinical records before finalisation.
Sample Size
A total of 14 patients who underwent thermal balloon endometrial ablation and fulfilled the eligibility criteria were included in the study.
As this was a retrospective case series, a total enumeration or census sampling technique was adopted. All eligible cases available during the defined study period were included.
Inclusion Criteria
The following criteria were applied to identify eligible cases:
1. Women who underwent thermal balloon endometrial ablation for abnormal uterine bleeding during the defined study period.
2. Women who had completed childbearing and were considered suitable for endometrial ablation.
3. Patients with documented preoperative clinical evaluation and relevant pelvic ultrasonographic findings.
4. Patients whose operative records confirmed the performance of thermal balloon endometrial ablation.
5. Patients with available postoperative outcome information sufficient to assess complications and subsequent hysterectomy.
Exclusion Criteria
The following conditions were considered relevant exclusion criteria for the retrospective review, subject to confirmation from the institutional eligibility protocol:
1. Pregnancy or intention to preserve future fertility.
2. Known or suspected endometrial malignancy or untreated atypical endometrial hyperplasia.
3. Active pelvic inflammatory disease or genital tract infection at the time of intervention.
4. Uterine cavity abnormalities considered unsuitable for the balloon ablation device.
5. Contraindications to the procedure or anaesthesia.
6. Cases in which thermal balloon ablation was planned but not performed.
7. Records with insufficient information to establish that the procedure had been completed.
The presence of uterine fibroids was not treated as an automatic exclusion criterion. Their size, location, and effect on uterine cavity configuration were considered relevant to procedural suitability.
Procedure and Methodology
The retrospective review was performed after identifying women who underwent thermal balloon endometrial ablation from the departmental operative registers. Eligible case records were retrieved and reviewed systematically using a predefined data collection format.
Preoperative assessment: The available clinical records were examined for age, parity, menstrual complaints, duration of abnormal uterine bleeding, previous medical treatment, associated medical disorders, and history of previous gynaecological or abdominal surgery. Particular attention was given to conditions such as hypothyroidism, hypertension, previous thromboembolic events, and other comorbidities that could influence treatment selection or perioperative management.
Preoperative pelvic ultrasonography findings were reviewed to document uterine size, endometrial thickness, endometrial polyps, fibroids, and other relevant abnormalities. Available records of endometrial sampling or histopathological examination were also reviewed to establish whether endometrial hyperplasia or malignancy had been excluded before ablation.
Thermal balloon endometrial ablation: The operative records were reviewed to identify the procedure performed, associated hysteroscopic assessment where documented, uterine cavity length, balloon inflation volume, treatment temperature, treatment duration, and intraoperative complications.
Thermal balloon endometrial ablation involved introducing a dedicated balloon catheter into the uterine cavity and inflating it with the recommended fluid medium according to the device protocol. Controlled thermal energy was delivered through the balloon to achieve destruction of the endometrial lining.
The uploaded operative sheets document procedural parameters such as balloon filling volumes of approximately 12-15 mL, recorded temperatures around 87-92°C, and treatment durations of approximately 12 minutes in several cases. These values were treated as individual recorded observations rather than uniform settings for all patients. The exact device, manufacturer-recommended settings, and procedure-specific measurements were to be verified against the original operative records.
Where additional procedures such as hysteroscopy, polypectomy, or fibroid resection were documented, these were recorded separately because they could influence postoperative bleeding outcomes.
Postoperative assessment: Postoperative records were reviewed for immediate recovery, pain, bleeding, fever, infection, uterine injury, readmission, and other documented adverse events. The discharge summaries and subsequent follow-up records were examined for persistent or recurrent abnormal uterine bleeding, additional treatment, repeat endometrial ablation, and subsequent hysterectomy.
According to the available clinical summary, all 14 patients had uneventful postoperative follow-up, and none required hysterectomy during the documented follow-up period.
Assessment of treatment outcomes: The principal outcomes were postoperative complications and hysterectomy-defined procedural failure. A patient was classified as having hysterectomy-defined treatment failure if hysterectomy was performed after thermal balloon endometrial ablation because of persistent or recurrent abnormal uterine bleeding or other ablation-related symptoms.
Clinical efficacy in terms of bleeding reduction, amenorrhoea, patient satisfaction, or requirement for additional medical treatment was assessed only when corresponding information was available in the clinical records.
Sample Processing
No laboratory sample processing was performed specifically for the retrospective study because the investigation was based on existing clinical and operative records.
Available preoperative histopathological findings, where documented, were reviewed to identify endometrial pathology and confirm the absence of contraindications to endometrial ablation. Endometrial biopsy reports, if available, were recorded according to their original histopathological diagnoses.
Clinical data were extracted from the original case sheets and entered into a structured master chart. Each patient was assigned a unique study identification number. Data entries were checked for completeness, consistency, duplicate records, and transcription errors before statistical analysis.
Statistical Methods
The collected data were organised in Microsoft Excel and analysed using IBM SPSS Statistics, version 26.0, or equivalent statistical software.
Continuous variables such as age, uterine cavity length, endometrial thickness, balloon inflation volume, procedural temperature, and treatment duration were summarised using mean and standard deviation for approximately normally distributed data. Median and interquartile range were considered for skewed variables.
Categorical variables, including parity categories, associated medical conditions, ultrasonographic findings, postoperative complications, requirement for repeat intervention, and hysterectomy, were expressed as frequencies and percentages.
Exact binomial confidence intervals were used for binary outcomes because of the small sample size and the presence of zero-event observations.
For the observed hysterectomy rate of 0/14, the two-sided 95% Clopper-Pearson confidence interval was approximately 0%-23.2%. Correspondingly, the 95% confidence interval for the hysterectomy-free proportion of 14/14 was approximately 76.8%-100%.
No formal between-group hypothesis testing was necessary because the study consisted of a single treatment group without a comparator. Exploratory comparisons were not considered reliable given the limited sample size.
A p-value below 0.05 was designated as statistically significant for any prespecified inferential analysis, although the primary analysis remained descriptive.
Data Collection
Data were collected retrospectively using a structured case record form developed for the study. The following information was extracted from the available clinical records:
Domain Variables recorded
Demographic characteristics Age, parity
Clinical characteristics Abnormal uterine bleeding, previous treatment, comorbidities
Medical and surgical history Hypothyroidism, thromboembolic disorders, previous abdominal or gynaecological surgery
Ultrasonographic findings Uterine size, fibroids, polyps, endometrial thickness
Procedural characteristics Uterine cavity length, balloon volume, temperature, treatment duration
Associated procedures Hysteroscopy, polypectomy, fibroid resection where documented
Postoperative outcomes Recovery, bleeding, pain, infection, complications
Follow-up outcomes Recurrent bleeding, repeat intervention, hysterectomy
Treatment failure Hysterectomy following ablation for persistent or recurrent symptoms
Data completeness was assessed for each variable. Missing or illegible entries were recorded as unavailable rather than assumed to be normal. Follow-up outcomes were assessed from documented clinical records and the supplied postoperative summary.
RESULTS
Table 1: Baseline demographic, clinical and ultrasonographic characteristics of women undergoing thermal balloon endometrial ablation
Characteristic Findings Statistical interpretation
Total study population 14 (100.0%) Census sample
Age, years 33-56 years among 13 legible records Descriptive range
Age, mean (SD) 44.31 (7.57), n=13 95% CI: 39.73-48.88
Age below 40 years 4/13 (30.8%) 95% CI: 9.1-61.4
Age 40 years and above 9/13 (69.2%) 95% CI: 38.6-90.9
Abnormal uterine bleeding 14 (100.0%) Inclusion criterion
Previous caesarean delivery Documented in multiple cases Exact frequency unverified
Uterine fibroids Documented in multiple cases Exact frequency unverified
Endometrial polyp Documented in at least one case Descriptive
Hypothyroidism Documented in multiple cases Exact frequency unverified
Table 1 presents the baseline demographic, clinical, and ultrasonographic characteristics of women who underwent thermal balloon endometrial ablation for abnormal uterine bleeding. The study included a total of 14 patients (100.0%), selected through a census sampling approach. Age information was available from 13 legible clinical records, with patients ranging from 33 to 56 years. The mean age was 44.31 ± 7.57 years, with a 95% confidence interval (CI) of 39.73-48.88 years, indicating that the study population predominantly comprised women in the late reproductive and perimenopausal age groups. Among the 13 patients with available age information, four (30.8%) were younger than 40 years, with a 95% CI of 9.1-61.4%, whereas nine (69.2%) were aged 40 years or above, with a 95% CI of 38.6-90.9%. These findings demonstrated that most patients undergoing thermal balloon endometrial ablation belonged to the older reproductive age group. Abnormal uterine bleeding was the primary indication for intervention in all 14 patients (100.0%). Previous caesarean delivery was documented in multiple patients, suggesting a history of previous obstetric surgical interventions in a proportion of the study population. Ultrasonographic evaluation revealed uterine fibroids in several cases, while endometrial polyps were identified in at least one patient. Associated medical conditions, particularly hypothyroidism, were also documented in multiple cases. However, the exact frequencies of previous caesarean delivery, uterine fibroids, endometrial polyps, and hypothyroidism could not be established from the available records.
Table 2: Clinical efficacy and postoperative treatment outcomes following thermal balloon endometrial ablation (N=14)
Outcome n (%) 95% CI
Thermal balloon ablation performed 14 (100.0) 76.8-100.0
Uneventful postoperative follow-up 14 (100.0) 76.8-100.0
Hysterectomy-free outcome 14 (100.0) 76.8-100.0
Hysterectomy-defined treatment success 14 (100.0) 76.8-100.0
Hysterectomy-defined treatment failure 0 (0.0) 0.0-23.2
Hysterectomy for persistent or recurrent bleeding 0 (0.0) 0.0-23.2
Complete resolution of abnormal uterine bleeding Not quantified
Postoperative amenorrhoea Not quantified
Table 2 demonstrates the clinical efficacy and postoperative treatment outcomes following thermal balloon endometrial ablation among the 14 women included in the study. All 14 patients (100.0%) underwent thermal balloon endometrial ablation, with a corresponding 95% confidence interval of 76.8-100.0%. Postoperative follow-up was reported to be uneventful in all 14 patients (100.0%), indicating favourable recovery during the documented observation period. The hysterectomy-free proportion was 100.0% (14/14), with a 95% CI of 76.8-100.0%, demonstrating that none of the patients required subsequent hysterectomy during follow-up. When treatment success was specifically defined as avoidance of hysterectomy, all 14 patients (100.0%) fulfilled this criterion. Conversely, the observed hysterectomy-defined treatment failure rate was 0.0% (0/14), with a 95% CI of 0.0-23.2%. No patient underwent hysterectomy because of persistent or recurrent abnormal uterine bleeding, suggesting favourable outcomes in terms of avoiding definitive surgical management. However, complete resolution of abnormal uterine bleeding and postoperative amenorrhoea were not separately quantified in the available clinical records. Therefore, the observed hysterectomy-free proportion could not be interpreted as evidence of complete symptomatic improvement in every patient. The relatively wide confidence intervals also reflected the limited precision associated with the small sample size.
Table 3: Procedural characteristics, safety and postoperative recovery following thermal balloon endometrial ablation
Parameter Recorded findings 95% CI
Balloon inflation volume 11-15 mL in clearly readable entries
Treatment temperature Approximately 87-92°C in recorded entries
Ablation duration 12 minutes in several recorded cases
Uterine cavity length Approximately 4-10 cm in readable entries
Uneventful postoperative follow-up 14/14 (100.0%) 76.8-100.0
Reported postoperative complications 0/14 (0.0%) 0.0-23.2
Subsequent hysterectomy 0/14 (0.0%) 0.0-23.2
Table 3 summarises the procedural characteristics, safety profile, and postoperative recovery of patients who underwent thermal balloon endometrial ablation. The available operative records documented balloon inflation volumes ranging from 11 to 15 mL in clearly readable entries, indicating variation in the volume used during the procedure. The recorded treatment temperature ranged approximately from 87°C to 92°C, while the ablation duration was documented as 12 minutes in several cases. Uterine cavity length varied approximately between 4 and 10 cm among the readable records, reflecting differences in uterine cavity dimensions across the study population. These procedural parameters provided information regarding the technical characteristics of thermal balloon endometrial ablation performed at the institution. However, complete individual measurements were not available for all 14 patients, preventing reliable calculation of overall means, standard deviations, and confidence intervals for these variables. Regarding postoperative safety, all 14 patients (100.0%) experienced an uneventful postoperative follow-up, with a 95% CI of 76.8-100.0%. No postoperative complications were reported among the study participants (0.0%), with a 95% CI of 0.0-23.2%. Furthermore, none of the patients required subsequent hysterectomy during the documented follow-up period, resulting in a hysterectomy rate of 0.0% (95% CI: 0.0-23.2%).
Table 4: Procedural failure and requirement for subsequent hysterectomy following thermal balloon endometrial ablation (N=14)
Outcome n (%) 95% CI
Patients completing thermal balloon ablation 14 (100.0) 76.8-100.0
Patients without subsequent hysterectomy 14 (100.0) 76.8-100.0
Hysterectomy for persistent abnormal uterine bleeding 0 (0.0) 0.0-23.2
Hysterectomy for recurrent abnormal uterine bleeding 0 (0.0) 0.0-23.2
Overall hysterectomy-defined procedural failure 0 (0.0) 0.0-23.2
Hysterectomy-free proportion 14 (100.0) 76.8-100.0
Repeat endometrial ablation Not documented
Other repeat surgical interventions Not documented
Table 4 presents the procedural failure rate and requirement for subsequent hysterectomy following thermal balloon endometrial ablation among the 14 patients included in the study. All 14 women (100.0%) completed thermal balloon endometrial ablation, with a corresponding 95% confidence interval of 76.8-100.0%. During the documented postoperative follow-up period, none of the patients underwent hysterectomy, resulting in a hysterectomy-free proportion of 100.0% (14/14), with a 95% CI of 76.8-100.0%. No hysterectomies were performed for persistent abnormal uterine bleeding (0.0%; 95% CI: 0.0-23.2%) or recurrent abnormal uterine bleeding (0.0%; 95% CI: 0.0-23.2%). Consequently, the overall hysterectomy-defined procedural failure rate was 0.0% (0/14), with a 95% CI of 0.0-23.2%. These findings demonstrated that none of the women required definitive surgical treatment by hysterectomy following thermal balloon endometrial ablation during the available observation period. Information regarding repeat endometrial ablation and other repeat surgical interventions was not separately documented in the available records; therefore, the overall reintervention rate could not be determined. The absence of hysterectomy-defined treatment failures suggested favourable outcomes in terms of uterine preservation and avoidance of major gynaecological surgery. However, the upper confidence limit of 23.2% indicated considerable statistical uncertainty because of the limited sample size. Moreover, the duration of follow-up was not specified, restricting interpretation of long-term treatment durability.
DISCUSSION
Table 1. Baseline demographic, clinical and ultrasonographic characteristics
The present study included 14 women undergoing thermal balloon endometrial ablation for abnormal uterine bleeding (AUB). Among the 13 patients with legible age records, the mean age was 44.31 ± 7.57 years (95% CI: 39.73-48.88), and nine women (69.2%) were aged ≥40 years. This age distribution was broadly comparable with that reported by Karimi-Zarchi et al. (2020)[1], whose study of 209 women treated with Cavaterm thermal balloon ablation reported a mean age of 45.9 ± 5.9 years. Both populations therefore predominantly represented women in the later reproductive years. However, chronological age alone does not establish perimenopausal status, and menopausal status was not separately documented in the present series.
Fibroids, an endometrial polyp and hypothyroidism were documented in the available records, indicating potentially heterogeneous causes of AUB. Munro et al. (2018)[2] emphasised systematic classification using the FIGO PALM-COEIN framework, which distinguishes structural causes, including polyps and leiomyomas, from non-structural causes. Consequently, the present population should not be regarded as a homogeneous group with exclusively non-structural bleeding. Because the frequencies, dimensions and cavity-distorting effects of the lesions were incompletely documented, their contribution to treatment outcomes could not be evaluated. Similarly, the presence of hypothyroidism did not establish that thyroid dysfunction was the principal cause of bleeding in individual patients.
Age is relevant to the interpretation of ablation outcomes. Beelen et al. (2019)[3], in a systematic review and meta-analysis, found that age ≤40 years was associated with increased surgical reintervention following endometrial ablation (OR: 1.58; 95% CI: 1.30-1.93). Previous tubal ligation (OR: 1.46; 95% CI: 1.23-1.73) and pre-existing dysmenorrhoea (OR: 2.12; 95% CI: 1.41-3.19) were also associated with reintervention. Although four women in the present study were younger than 40 years, its age categories differed slightly from those used in the review, and the absence of observed failures prevented meaningful assessment of age-related risk. The predominance of older women may have contributed to favourable outcomes, but this remains an interpretation rather than a demonstrated association.
Evidence from other ablation technologies also highlights the importance of baseline characteristics. Lybol et al. (2018)[4] studied 486 women undergoing NovaSure ablation and reported that 19.3% required secondary treatment over a median follow-up of 45 months. Younger age, previous sterilisation, dysmenorrhoea and intramural leiomyomas were independent predictors of failure. Soini et al. (2017)[5], in a Finnish population-based study, likewise identified associations between subsequent hysterectomy and factors including leiomyomas, younger age and a history of at least two caesarean deliveries. These findings support detailed documentation of obstetric history and uterine pathology. Nevertheless, they cannot be directly applied to the present thermal balloon series, in which the exact frequency and number of previous caesarean deliveries were unverified.
Table 2. Clinical efficacy and postoperative treatment outcomes
All 14 patients remained free from hysterectomy during the documented observation period, corresponding to a hysterectomy-free proportion of 100.0% (95% CI: 76.8-100.0%). This finding is encouraging, but it represents a narrowly defined outcome. Completion of ablation, uncomplicated recovery, avoidance of hysterectomy, improvement in bleeding and amenorrhoea are distinct endpoints. Since postoperative bleeding and amenorrhoea were not quantified, the present results cannot establish complete symptomatic success in every patient.
Direct evidence supporting thermal balloon ablation was provided by Jain et al. (2016)[6], who randomised 40 women with leiomyoma-associated heavy menstrual bleeding to thermal balloon ablation or vaginal hysterectomy. Among the 20 women allocated to balloon ablation, 19 were amenorrhoeic and one was hypomenorrhoeic at six months. One woman subsequently developed recurrent heavy bleeding and underwent hysterectomy at 12 months. This study demonstrates that favourable early bleeding outcomes can coexist with later treatment failure. Unlike the present series, it assessed menstrual outcomes at specified follow-up intervals, making its efficacy findings more directly interpretable.
Mohamadianamir et al. (2023)[7], in a randomised comparison of thermal balloon and hysteroscopic ablation, reported treatment success at one year in 91.2% of the Cavaterm group and 76.0% of the hysteroscopy group. These findings support the potential effectiveness of thermal balloon ablation, but their success definition incorporated menstrual outcomes rather than hysterectomy avoidance alone. Similarly, Penninx et al. (2016)[8] reported 12-month amenorrhoea rates of 23% after Thermablate balloon ablation and 56% after bipolar radiofrequency ablation. Satisfaction was 69% and 87%, respectively, while reintervention occurred in 12% and 10%. These results illustrate why the present 100% hysterectomy-free proportion should not be described as superior to published amenorrhoea or satisfaction rates: the outcomes measure different aspects of treatment effectiveness.
Bofill Rodriguez et al. (2019)[9], in a Cochrane review, found broadly comparable bleeding improvement and amenorrhoea outcomes between first- and second-generation endometrial ablation techniques, although the certainty of evidence varied. The review assessed multiple outcomes, including bleeding, quality of life, satisfaction and further surgery. This multidimensional approach is particularly relevant to the present study, where absence of hysterectomy was measurable but patient-reported benefit was not. Consequently, the findings support observed uterine preservation but provide insufficient evidence to quantify the magnitude of bleeding reduction.
Comparative trials further demonstrate the importance of patient-centred outcomes. Beelen et al. (2021)[10] reported surgical reintervention in 10% of women allocated to bipolar radiofrequency ablation compared with 27% allocated to a levonorgestrel-releasing intrauterine system (RR: 2.64; 95% CI: 1.49-4.68, comparing the intrauterine-system strategy with ablation). Cooper et al. (2019)[11], in the HEALTH trial, found satisfaction at 15 months in 87% of women allocated to endometrial ablation and 97% allocated to laparoscopic supracervical hysterectomy. Deehan et al. (2023)[12], reviewing 12 randomised trials involving 2,028 women, found more favourable bleeding outcomes following hysterectomy, alongside the greater operative and recovery burden of that procedure. Together, these studies show that hysterectomy avoidance is valuable but should be interpreted alongside bleeding relief, satisfaction, recovery and subsequent treatment. The present uncontrolled series cannot establish comparative effectiveness against either medical treatment or hysterectomy.
Table 3. Procedural characteristics, safety and postoperative recovery
The readable operative entries documented balloon inflation volumes of 11-15 mL, temperatures of approximately 87-92°C and a treatment duration of 12 minutes in several patients. Recorded uterine cavity lengths ranged approximately from 4 to 10 cm. These findings describe the institutional records, but incomplete measurements and the absence of a verified device model prevent assessment of protocol consistency. In particular, uterine sounding length, uterocervical length and endometrial cavity length should not be assumed to be interchangeable. The recorded temperature and duration should therefore not be presented as a standard protocol applicable to every thermal balloon system.
Laberge et al. (2015)[13] described endometrial ablation as an established minimally invasive treatment for selected women with AUB and emphasised appropriate preoperative evaluation and technique selection. The updated guideline by Leyland et al. (2024)[14] similarly addressed safe use of ablation in women with benign AUB, with or without structural abnormalities. In relation to the present findings, these publications support verification of the device, cavity measurements, uterine pathology and procedural documentation before interpreting technical suitability. The absence of reported complications cannot, by itself, confirm that each recorded procedural parameter complied with the relevant device requirements.
No postoperative complications were reported among the 14 women, giving an observed complication proportion of 0.0% with an exact 95% CI of 0.0-23.2%. This is reassuring as a descriptive finding but remains imprecise. The upper confidence limit indicates that a clinically meaningful underlying complication frequency cannot be excluded by this small series. Moreover, “uneventful follow-up” is a general description and does not establish the absence of each specific outcome, such as infection, prolonged discharge, haematometra, pain or thermal injury, unless these were actively assessed and recorded. Although Bofill Rodriguez et al. (2019)[9] found that second-generation techniques generally required shorter operating times than first-generation procedures, the present study did not provide sufficiently complete operative-time or recovery data to demonstrate a comparable advantage.
Longer-term safety also requires outcomes beyond immediate postoperative recovery. Kohn et al. (2018)[15], in a systematic review of pregnancy after endometrial ablation, documented serious reproductive complications, reinforcing that ablation should not be interpreted as a contraceptive procedure. Oderkerk et al. (2022)[16], in a systematic review of endometrial cancer after ablation, found no evidence that previous ablation was associated with increased endometrial cancer development or diagnosis at a more advanced stage. However, this population-level finding does not establish oncological safety in an individual patient or replace pre-ablation assessment of benign pathology. Since reproductive outcomes, histopathological confirmation and long-term surveillance were not systematically reported in the present tables, the safety conclusion should remain limited to the complications documented during available follow-up.
Table 4. Procedural failure and subsequent hysterectomy
No hysterectomies for persistent or recurrent AUB were documented, resulting in a hysterectomy-defined failure proportion of 0.0% (95% CI: 0.0-23.2%). This represents the same hysterectomy endpoint reported in Table 2 and should not be treated as independent evidence of effectiveness. Furthermore, because repeat ablation and other surgical interventions were not documented, the overall surgical reintervention proportion could not be determined. Absence of documentation should not be converted into an assumed zero-event count.
The importance of follow-up duration was demonstrated by Oderkerk et al. (2023)[17], whose systematic review and meta-analysis found that hysterectomy risk following nonresectoscopic endometrial ablation increased from approximately 4.3% at one year to 12.4% at five years. The present zero-hysterectomy observation does not conflict with these estimates because both lie within its wide confidence interval. For illustration, if all 14 women had a comparable five-year follow-up and each had a 12.4% hysterectomy probability, the probability of observing no hysterectomies would still be approximately 15.7%, calculated as \(0.876^{14}\). This is a statistical illustration, not an estimate of the present cohort’s five-year outcome, since its follow-up duration is unspecified.
Klebanoff et al. (2017)[18] reported surgical reintervention in 15.6% of women following second-generation ablation, including hysterectomy in 13.9% and repeat ablation in 1.8%. Their results demonstrate that a hysterectomy-only endpoint misses some subsequent procedures. McGee et al. (2024)[19], in a population-based Ontario cohort of 76,446 patients, reported continued accumulation of hysterectomies during long-term follow-up, approaching 29% by 15 years. These larger studies provide context for treatment durability but are not directly comparable with a 14-patient thermal balloon series because of differences in technology, case selection, outcome ascertainment and observation time.
Wortman et al. (2015)[20] described late-onset ablation failure as a clinically important phenomenon that can involve recurrent bleeding, pain and the need for additional intervention. This reinforces the distinction between successful completion of the initial procedure and durable clinical benefit. Huijs et al. (2024)[21], reporting long-term follow-up of a randomised trial, found cumulative surgical reintervention in 19.1% of the radiofrequency ablation group compared with 35.3% of the levonorgestrel intrauterine-system group. Although this was not a thermal balloon study, it illustrates that subsequent treatment remains possible despite initially successful ablation.
Finally, Bofill Rodriguez et al. (2021)[22], in their Cochrane comparison of endometrial resection or ablation with hysterectomy, identified the trade-off between a less invasive initial procedure and the possibility of further surgery. Accordingly, the present findings are most appropriately interpreted as favourable documented outcomes in a small retrospective series. They support the feasibility of thermal balloon ablation and observed avoidance of hysterectomy, but do not establish a zero long-term failure rate. Standardised assessment of menstrual blood loss, haemoglobin, pain, satisfaction, additional treatment and the duration and completeness of follow-up would strengthen subsequent evaluation.
CONCLUSION
Thermal balloon endometrial ablation was associated with favourable documented postoperative outcomes in this retrospective series of 14 women with abnormal uterine bleeding. All patients completed the procedure, and no postoperative complications or subsequent hysterectomies were recorded during the available follow-up. However, the absence of quantified bleeding outcomes and amenorrhoea rates precluded confirmation of complete symptomatic resolution. The small sample and unspecified follow-up duration also limited conclusions regarding long-term safety and treatment durability. These findings support further evaluation of thermal balloon ablation as a uterine-preserving treatment in appropriately selected women, using larger studies with standardised outcome assessment and clearly defined follow-up.
LIMITATIONS OF THE STUDY
The principal limitation was the small sample size of 14 patients, which restricted statistical precision and generalisability. Although no complications or hysterectomies were recorded, the corresponding exact 95% confidence intervals extended from 0.0% to 23.2%; therefore, clinically meaningful event rates could not be excluded. The retrospective design introduced potential selection and information biases because data completeness depended on existing clinical records. Some handwritten entries were incomplete or illegible, with age available for only 13 patients and insufficient information to establish the exact frequencies of previous caesarean delivery, fibroids and hypothyroidism.
The duration and completeness of postoperative follow-up were not specified, limiting assessment of delayed complications, recurrent bleeding and subsequent hysterectomy. Standardised measures of menstrual blood loss, postoperative amenorrhoea, haemoglobin improvement, pain, patient satisfaction and quality of life were unavailable. Consequently, treatment success could be assessed only through documented hysterectomy avoidance, which does not necessarily indicate adequate bleeding control. Repeat ablation and other interventions were not separately documented, preventing estimation of the overall reintervention rate. Incomplete procedural measurements and unverified device details restricted technical comparisons with other studies. Finally, the absence of a comparison group prevented conclusions regarding relative efficacy, safety or recovery compared with medical treatment, other ablation techniques or hysterectomy.